SPL 3.13% 9.9¢ starpharma holdings limited

Covid-19 is not over by a long shot ladies and gentlemen, page-57

  1. 1,790 Posts.
    lightbulb Created with Sketch. 315
    I personally think the real issue now is how to avoid phase 3 DEP trials i.e. what needs to be done to satisfy 505(b)(2) requirements. It has high cost and time delay implications.
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.